- Home
- applications
- finland
- drug development
Drug Development Applications For The Served Medical Health Care Industry Available In Finland
6 applications found
For more than 20 years, we have been bringing our research and expertise to this therapeutic area. We have focused on developing novel drugs in areas of unmet need, such as autosomal dominant polycystic kidney disease and hyponatremia, that have changed the treatment landscape. ...
ByOtsuka America Pharmaceutical, Inc based in Princeton, NEW JERSEY (USA)
Effecting an estimated one million Americans, Crohn's disease can be highly debilitating and remains a serious burden for both patients and healthcare systems. ...
ByRedHill Biopharma Ltd. based in Tel-Aviv, ISRAEL
Thermal Management: Pyroid HT pyrolytic graphite thermal spreaders and thermal vias are a powerful new material solution in the battle against thermal heat in state-of-the-art electronic circuits and devices. HT material matches the heat spreading capability of CVD diamond at 1700 W/mK but at substantially better economics. ...
ByCETCO based in New York, NEW YORK (USA)
In modern healthcare, microscopic images, X-rays, CT, PET and MRI scans generate a lot of data which provides critical indicators for patient care and research. AI can help specialists manage this data. Robovision can provide or develop powerful tools to enhance the detection, classification, and quantification of lesions or ...
ByRobovision BV based in Ghent, BELGIUM
Increase clinical translation with Organ-Chips for ADME-Tox assessments. Accurate ADME-Tox profiling of preclinical drug candidates remains a challenge. Preclinical ADME-Tox (Absorption, Distribution, Metabolism, Excretion, and Toxicity) studies are pivotal to predicting human response. However, approximately 30% of drugs fail during human clinical trials due to adverse reactions despite promising preclinical study results, and another 60% fail due to lack of efficacy. As companies broaden the modality toolbox ...
ByEmulate based in Boston, MASSACHUSETTS (USA)
Aptamers are short strands of DNA or RNA with unique secondary and tertiary structures that enable highly selective binding to various types of targets. While aptamers are similar to antibodies in their ability to specifically bind with high affinity, there are some key differences between antibodies and aptamers which have prompted an increase in aptamer development projects. Several hot areas for aptamers, along with specific aptamer advantages, are outlined below. ...
ByBase Pair Biotechnologies, Inc. based in Pearland, TEXAS (USA)